HHS Shifts Remdesivir Distribution To Gilead As Supply Crunch Eases
AmerisourceBergen will continue to serve as the sole US distributor of Veklury (remdesivir) through the end of this year and will continue to sell the the COVID-19 treatment directly to hospitals.
You may also be interested in...
Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesivir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.
Gilead’s COVID treatment will be the first product tracked in a system that could eventually help allocate vaccines and other therapeutics.
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.